RBC Capital Reiterates Buy Rating on Edgewise Therapeutics

RBC Capital maintains its buy rating on Edgewise Therapeutics with a $59 price target.

Written by EarningsIQ · Published Jun 17, 2026, 12:02 PM EDT · Updated Jun 20, 2026, 3:01 PM EDT

Key Points

RBC Capital reiterated its buy rating on Edgewise Therapeutics, Inc. (EWTX) with a price target of $59 on June 17, 2026.
Edgewise Therapeutics, trading at $33.95, has a market cap of $3.65 billion and a 52-week high of $40.77.
Insiders recently bought shares, while analysts maintain a buy consensus with a mean target price of $46.08.

Important disclosure: EarningsIQ is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.

RBC Capital reiterated its buy rating on Edgewise Therapeutics, Inc. (NasdaqGS: EWTX) on June 17, 2026, setting a price target of $59. Analyst Leonid Timashev maintained a positive outlook on the biopharmaceutical company, which focuses on therapies for muscle disorders.

Other Institutional Activity in Edgewise Therapeutics

ORBIMED ADVISORS LLC held steady with 15.52 million shares valued at about $488.8 million. RA CAPITAL MANAGEMENT, L.P. also maintained its position with 10.43 million shares worth $328.5 million. PARADIGM BIOCAPITAL ADVISORS LP increased its holdings by 823,828 shares to a total of 7.37 million shares, valued at $232 million. Meanwhile, BLACKROCK, INC. reduced its stake by 157,585 shares, ending with 6.47 million shares valued at $203.9 million. JANUS HENDERSON GROUP PLC added 1.35 million shares, bringing their total to 5.92 million shares worth $186.3 million.

Edgewise Therapeutics, Inc. Stock Up 5.7%

Shares of Edgewise Therapeutics traded at $33.95 on the NasdaqGS. The company has a market cap of approximately $3.65 billion. The stock's 52-week range is between $12.15 and $40.77, with a 50-day moving average of $33.68 and a 200-day moving average of $25.78. The company is not currently profitable, as indicated by its negative forward P/E ratio of -15.34. Its beta is 0.304, suggesting lower volatility compared to the market.

Insider Buying and Selling at Edgewise Therapeutics, Inc.

On June 5, 2026, several insiders bought shares in Edgewise Therapeutics. Jonathan Fox, Christopher Martin, and Badreddin Edris acquired 16,377, 16,377, and 8,188 shares respectively. Meanwhile, on May 5, 2026, CMO Joanne Donovan sold 50,000 shares at an average price of $38.57 and bought 50,000 shares at $7.08.

Analysts Set New Price Targets

On June 17, 2026, RBC Capital maintained its buy rating with a $59 target. Goldman Sachs also maintained a hold rating with a $32 target on the same day. On June 16, 2026, HC Wainwright & Co. reiterated a buy rating with a $45 target. Overall, the consensus among analysts is a buy, with an average target price of $46.08 based on 12 opinions.

About Edgewise Therapeutics

Edgewise Therapeutics, Inc. is a biopharmaceutical company based in Boulder, Colorado. It focuses on discovering and developing therapies for muscle disorders. The company's lead candidate, sevasemten, is in Phase II trials for treating dystrophinopathies like Duchenne and Becker muscular dystrophy. Edgewise is also working on EDG-7500 for cardiac disorders and EDG-15400 for heart failure. The company was founded in 2017 and is led by CEO Dr. Kevin Koch.

Bottom Line

RBC Capital's reiteration of a buy rating reflects continued confidence in Edgewise Therapeutics' potential. Investors track such analyst actions closely to gauge market sentiment. However, it's important to remember that these ratings are based on past data and do not predict future performance.

Get Edgewise Therapeutics, Inc. alerts

New 13F filings, insider trades, and analyst moves on $EWTX, sent to your inbox. Free, and you can unsubscribe anytime.

This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.